260 related articles for article (PubMed ID: 21315119)
1. Characterisation and tumour targeting of PEGylated polylysine dendrimers bearing doxorubicin via a pH labile linker.
Kaminskas LM; Kelly BD; McLeod VM; Sberna G; Owen DJ; Boyd BJ; Porter CJ
J Control Release; 2011 Jun; 152(2):241-8. PubMed ID: 21315119
[TBL] [Abstract][Full Text] [Related]
2. Doxorubicin-conjugated PEGylated dendrimers show similar tumoricidal activity but lower systemic toxicity when compared to PEGylated liposome and solution formulations in mouse and rat tumor models.
Kaminskas LM; McLeod VM; Kelly BD; Cullinane C; Sberna G; Williamson M; Boyd BJ; Owen DJ; Porter CJ
Mol Pharm; 2012 Mar; 9(3):422-32. PubMed ID: 22233281
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin Conjugation and Drug Linker Chemistry Alter the Intravenous and Pulmonary Pharmacokinetics of a PEGylated Generation 4 Polylysine Dendrimer in Rats.
Leong NJ; Mehta D; McLeod VM; Kelly BD; Pathak R; Owen DJ; Porter CJH; Kaminskas LM
J Pharm Sci; 2018 Sep; 107(9):2509-2513. PubMed ID: 29852134
[TBL] [Abstract][Full Text] [Related]
4. Capping methotrexate α-carboxyl groups enhances systemic exposure and retains the cytotoxicity of drug conjugated PEGylated polylysine dendrimers.
Kaminskas LM; Kelly BD; McLeod VM; Sberna G; Boyd BJ; Owen DJ; Porter CJ
Mol Pharm; 2011 Apr; 8(2):338-49. PubMed ID: 21171585
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and tumor disposition of PEGylated, methotrexate conjugated poly-l-lysine dendrimers.
Kaminskas LM; Kelly BD; McLeod VM; Boyd BJ; Krippner GY; Williams ED; Porter CJ
Mol Pharm; 2009; 6(4):1190-204. PubMed ID: 19453158
[TBL] [Abstract][Full Text] [Related]
6. Novel folated and non-folated pullulan bioconjugates for anticancer drug delivery.
Scomparin A; Salmaso S; Bersani S; Satchi-Fainaro R; Caliceti P
Eur J Pharm Sci; 2011 Apr; 42(5):547-58. PubMed ID: 21371555
[TBL] [Abstract][Full Text] [Related]
7. PEGylated polylysine dendrimers increase lymphatic exposure to doxorubicin when compared to PEGylated liposomal and solution formulations of doxorubicin.
Ryan GM; Kaminskas LM; Bulitta JB; McIntosh MP; Owen DJ; Porter CJH
J Control Release; 2013 Nov; 172(1):128-136. PubMed ID: 23954628
[TBL] [Abstract][Full Text] [Related]
8. Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors.
Han L; Huang R; Liu S; Huang S; Jiang C
Mol Pharm; 2010 Dec; 7(6):2156-65. PubMed ID: 20857964
[TBL] [Abstract][Full Text] [Related]
9. Hydrophobic cavity formed by oligopeptide for doxorubicin delivery based on dendritic poly(L-lysine).
Niidome T; Yamauchi H; Takahashi K; Naoyama K; Watanabe K; Mori T; Katayama Y
J Biomater Sci Polym Ed; 2014; 25(13):1362-73. PubMed ID: 25040893
[TBL] [Abstract][Full Text] [Related]
10. Polyethylene glycol-conjugated hyaluronic acid-ceramide self-assembled nanoparticles for targeted delivery of doxorubicin.
Cho HJ; Yoon IS; Yoon HY; Koo H; Jin YJ; Ko SH; Shim JS; Kim K; Kwon IC; Kim DD
Biomaterials; 2012 Feb; 33(4):1190-200. PubMed ID: 22074664
[TBL] [Abstract][Full Text] [Related]
11. pH triggered doxorubicin delivery of PEGylated glycolipid conjugate micelles for tumor targeting therapy.
Hu FQ; Zhang YY; You J; Yuan H; Du YZ
Mol Pharm; 2012 Sep; 9(9):2469-78. PubMed ID: 22827551
[TBL] [Abstract][Full Text] [Related]
12. Ligand anchored dendrimers based nanoconstructs for effective targeting to cancer cells.
Gupta U; Dwivedi SK; Bid HK; Konwar R; Jain NK
Int J Pharm; 2010 Jun; 393(1-2):185-96. PubMed ID: 20382210
[TBL] [Abstract][Full Text] [Related]
13. A duplex oligodeoxynucleotide-dendrimer bioconjugate as a novel delivery vehicle for doxorubicin in in vivo cancer therapy.
Lee IH; Yu MK; Kim IH; Lee JH; Park TG; Jon S
J Control Release; 2011 Oct; 155(1):88-95. PubMed ID: 20854858
[TBL] [Abstract][Full Text] [Related]
14. Vascular targeting of doxorubicin using cationic liposomes.
Wu J; Lee A; Lu Y; Lee RJ
Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
[TBL] [Abstract][Full Text] [Related]
15. Amphiphilic multi-arm-block copolymer conjugated with doxorubicin via pH-sensitive hydrazone bond for tumor-targeted drug delivery.
Prabaharan M; Grailer JJ; Pilla S; Steeber DA; Gong S
Biomaterials; 2009 Oct; 30(29):5757-66. PubMed ID: 19643472
[TBL] [Abstract][Full Text] [Related]
16. Dendronized nanoconjugates of lysine and folate for treatment of cancer.
Jain K; Gupta U; Jain NK
Eur J Pharm Biopharm; 2014 Aug; 87(3):500-9. PubMed ID: 24698808
[TBL] [Abstract][Full Text] [Related]
17. A new system for targeted delivery of doxorubicin into tumor cells.
Yabbarov NG; Posypanova GA; Vorontsov EA; Obydenny SI; Severin ES
J Control Release; 2013 Jun; 168(2):135-41. PubMed ID: 23517785
[TBL] [Abstract][Full Text] [Related]
18. PEGylated Poly(amidoamine) dendrimer-based dual-targeting carrier for treating brain tumors.
He H; Li Y; Jia XR; Du J; Ying X; Lu WL; Lou JN; Wei Y
Biomaterials; 2011 Jan; 32(2):478-87. PubMed ID: 20934215
[TBL] [Abstract][Full Text] [Related]
19. Octreotide-modification enhances the delivery and targeting of doxorubicin-loaded liposomes to somatostatin receptors expressing tumor in vitro and in vivo.
Sun M; Wang Y; Shen J; Xiao Y; Su Z; Ping Q
Nanotechnology; 2010 Nov; 21(47):475101. PubMed ID: 21030757
[TBL] [Abstract][Full Text] [Related]
20. A pharmaceutical study of doxorubicin-loaded PEGylated nanoparticles for magnetic drug targeting.
Gautier J; Munnier E; Paillard A; Hervé K; Douziech-Eyrolles L; Soucé M; Dubois P; Chourpa I
Int J Pharm; 2012 Feb; 423(1):16-25. PubMed ID: 21703340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]